28 August 2024
28 August 2024
The ACURATE Prime Aortic Valve comes as a follow on to the company’s multi-sized ACURATE neo2 system designed to treat severe aortic stenosis.
Developed by Aesculap and Miethke, the M.scio system is designed for monitoring intracranial pressure in hydrocephalus patients.
The device is claimed to be the smallest profile surgical LAA device in the market.
The Accuray Helix system is tailored to deliver precise, targeted radiation treatments for a variety of cancers.
The Phase III study evaluating the company’s growth hormone test failed to meet the primary endpoint, leading Cosciens’ stock to dip by 32%.
The TSO test profiles over 500 genes in solid tumors to identify immuno-oncology or clinically actionable biomarker.
Emergency department enrolment will continue into 2025 for a subsequent and separate 510(k) application.
The partnership with Pancreatic Cancer Europe will see patients and providers supplied with a comprehensive search engine to access relevant clinical trials.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
